MATINAS BIOPHARMA HOLDINGS, INC. Proceeds from Stock Options Exercised
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Proceeds from Stock Options Exercised of $99.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2024-03-27
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from stock options exercised for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from stock options exercised for the quarter ending 2022-09-30 was $0.00.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from stock options exercised for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from stock options exercised for the quarter ending 2022-03-31 was $99.00K, a 91.83% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from stock options exercised for fiscal 2022 was $99.00K, a 93.00% decline from fiscal 2021.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from stock options exercised for fiscal 2021 was $1.42M, a 135.95% increase from fiscal 2020.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from stock options exercised for fiscal 2020 was $599.71K, a 1887.45% increase from fiscal 2019.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from stock options exercised for fiscal 2019 was $30.18K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 3 month as first filed | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 6 month as first filed | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 9 month as first filed | Proceeds from Stock Options Exercised 12 month | Proceeds from Stock Options Exercised 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $0.00 derived: sum of 2 quarters · filed 2024-03-27 | $0.00 derived: sum of 3 quarters · filed 2024-03-27 | $99.00K 10-K · filed 2024-03-27 | ||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $99.00K 10-Q · filed 2023-11-08 | $99.44K 10-Q · filed 2022-11-02 | $113.34K derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $99.00K 10-Q · filed 2023-08-09 | $99.44K 10-Q · filed 2022-08-11 | $113.34K derived: sum of 3 quarters · filed 2023-08-09 | $113.34K derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $99.00K 10-Q · filed 2023-05-10 | $99.44K 10-Q · filed 2022-05-12 | $113.34K derived: sum of 2 quarters · filed 2023-05-10 | $113.34K derived: sum of 3 quarters · filed 2023-05-10 | $301.97K derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $14.34K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $14.34K derived: sum of 2 quarters · filed 2023-03-15 | $202.97K derived: sum of 3 quarters · filed 2023-03-15 | $1.42M 10-K · filed 2023-03-15 | $1.42M 10-K · filed 2022-03-08 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $188.63K derived: sum of 2 quarters · filed 2022-11-02 | $1.40M 10-Q · filed 2022-11-02 | $1.89M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | $188.63K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.40M 10-Q · filed 2022-08-11 | $1.89M derived: sum of 3 quarters · filed 2022-08-11 | $1.96M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $1.21M 10-Q · filed 2022-05-12 | $1.70M derived: sum of 2 quarters · filed 2022-05-12 | $1.77M derived: sum of 3 quarters · filed 2022-05-12 | $1.77M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $492.39K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | $557.21K derived: sum of 2 quarters · filed 2022-03-11 | $557.21K derived: sum of 3 quarters · filed 2022-03-11 | $599.71K 10-K/A · filed 2022-03-11 | ||||
| 2020-09-30 | $64.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $64.83K derived: sum of 2 quarters · filed 2021-11-08 | $107.33K 10-Q · filed 2021-11-08 | |||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $42.50K 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | $42.50K 10-Q · filed 2021-05-10 | |||||||
| 2019-12-31 | $30.18K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |